Heart rhythm study for blood cancer patients starting new treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at whether certain blood cancer treatments increase the risk of an irregular heartbeat called atrial fibrillation. It may help doctors understand which patients need closer heart monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).
- You are about to start a new treatment for your blood cancer, such as a BTK inhibitor (like ibrutinib) or a non-BTK therapy (like venetoclax).
- You have not taken a BTK inhibitor before.
- You do not have a history of ongoing (persistent) atrial fibrillation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
This study checks how often abnormal heart rhythms happen when you start a BTK inhibitor (used for certain blood cancers). It uses a small implanted heart monitor to record your rhythm continuously before and after starting the medication, so doctors can detect and manage problems early.
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
This study is following people with atrial fibrillation to learn more about heart health when other conditions like obesity, diabetes, or high blood pressure are present. It could help improve treatments in the future.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.